Glaxo to Pay $3 Billion for
Unapproved Marketing of Paxil & Wellbutrin

In agreeing to settle the largest case of health care fraud in U.S. history, GlaxoSmithKline pled guilty today to marketing Paxil for teens and children and to advertising Wellbutrin for weight loss and sexual dysfuntion. Glaxo will pay $1 billion in criminal fines and $2 billion in civil fines for activities such as distributing a misleading journal article and providing kickbacks to doctors. “Today’s historic settlement is a major milestone in our efforts to stamp out health care fraud,” said the deputy secretary of health and human services in a statement. Article →  Related Item: GlaxoSmithKline settles healthcare fraud case for $3 billion Glaxo Agrees to Pay $3 Billion in Fraud Settlement